Zydus Lifesciences Ltd.
- MCAP
- ₹1.12 lakh Cr
- P/E
- 22.87x
- P/B
- 4.12x
- DIV YLD
- 0.09%
- VOLUME
- —
Fundamental snapshot
Latest available consolidated resultsQuarterly results
Consolidated · ₹ crore, except earnings per share
| Metric | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 6,037.9 | 6,780.4 | 7,434.4 | 7,802 |
| Net profit | 1,233.4 | 965.1 | 1,341.3 | 952.4 |
| EPS (₹) | 12.51 | 10.36 | 12.65 | 9.35 |
Reporting periods may lag new filings. Compare the same quarter across years to account for seasonality.
Profit & cash flow
Annual consolidated figures · ₹ crore
Profit and operating cash flow measure different things. Compare them over several years and review working-capital changes.
Shareholding pattern
As of Jun 2026
Ownership percentages are reported snapshots. They do not measure daily FII or DII flows.
Balance sheet
Consolidated · Mar 2026 · ₹ crore
- Total assets
- 52,407
- Shareholders’ funds
- 27,111
- Cash & bank balances
- 1,417
Review assets alongside liabilities, debt maturity and cash generation. Compare companies within the same industry.
Financial questions
Answers derived from the reporting periods shown on this page.
What are the latest available quarterly results for Zydus Lifesciences?
For the quarter ended Jun 2026, the available consolidated data shows sales of ₹7,802 Cr and net profit of ₹952 Cr. Compare the same quarter a year earlier to account for seasonality. These are the latest figures in this dataset; check the exchange for subsequent filings.
How much operating cash flow does Zydus Lifesciences generate?
For the year ended Mar 2026, operating cash flow was ₹2,117 Cr and reported free cash flow was −₹555 Cr. Compare cash generation with net profit for the same year and review working-capital movements in the cash flow statement.
What is the shareholding pattern of Zydus Lifesciences?
The Jun 2026 shareholding snapshot records promoters at 75.01%, foreign institutions at 6.89%, domestic institutions at 11.19%, public & others at 6.9%. This is a dated ownership snapshot, not a record of daily institutional buying or selling.
What is the debt-to-equity ratio of Zydus Lifesciences?
The debt-to-equity ratio is 0.31x for Mar 2026. Interpret leverage alongside the company's industry, interest costs and ability to generate cash. Financial-sector balance sheets require different comparisons from industrial businesses.
What does ZYDUSLIFE's P/E ratio mean?
The available valuation snapshot reports a P/E of 22.87x. P/E compares the share price with earnings per share and can change with prices, earnings updates and accounting adjustments. It does not by itself establish whether the stock is cheap or expensive.
Where can I review financial statements for Zydus Lifesciences?
The analysis workspace includes quarterly results, profit and loss, balance sheet, cash flow, financial ratios and shareholding history. The public balance-sheet snapshot covers Mar 2026. Sign in to use the detailed analysis tools, and verify unusual items against the original exchange filings.
Related companies
Open company fundamentals for a comparison. Business mix and accounting may differ.
ZYDUSLIFE options & derivatives
Connect company fundamentals with options positioning.
Reporting notes
Figures shown on this page may contain errors, omissions, or outdated information. Verify financial data and calculations against the company’s original filings before relying on them.